Letters Clostridium difficile

Monoclonal antibody treatment

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1850 (Published 01 April 2010) Cite this as: BMJ 2010;340:c1850
  1. Oscar M Jolobe, retired geriatrician1
  1. 1Manchester Medical Society, c/o John Rylands University Library, Manchester M13 9PP
  1. oscarjolobe{at}yahoo.co.uk

    The risk of relapse of Clostridium difficile diarrhoea is 20-25%1 2 3 and can be mitigated by co-prescription of monoclonal antibodies directed against …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription